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Abstract
Background: A high perioperative inspiratory oxygen fraction may reduce the risk of surgical site
infections, as bacterial eradication by neutrophils depends on wound oxygen tension. Two trials
have shown that a high perioperative inspiratory oxygen fraction (FiO2 = 0.80) significantly reduced
risk of surgical site infections after elective colorectal surgery, but a third trial was stopped early
because the frequency of surgical site infections was more than doubled in the group receiving FiO2
= 0.80. It has not been settled if a high inspiratory oxygen fraction increases the risk of pulmonary
complications, such as atelectasis, pneumonia and respiratory failure. The aim of our trial is to
assess the potential benefits and harms of a high perioperative oxygen fraction in patients
undergoing abdominal surgery.
Methods and design: The PROXI-Trial is a randomized, patient- and assessor blinded trial of
perioperative supplemental oxygen in 1400 patients undergoing acute or elective laparotomy in 14
Danish hospitals. Patients are randomized to receive either 80% oxygen (FiO2 = 0.80) or 30%
oxygen (FiO2 = 0.30) during surgery and for the first 2 postoperative hours. The primary outcome
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is surgical site infection within 14 days. The secondary outcomes are: atelectasis, pneumonia,
respiratory failure, re-operation, mortality, duration of postoperative hospitalization, and
admission to intensive care unit. The sample size allows detection of a 33% relative risk reduction
in the primary outcome with 80% power.
Discussion: This trial assesses benefits and harms of a high inspiratory oxygen fraction, and the
trial may be generalizable to a general surgical population undergoing laparotomy.
Trial registration: ClinicalTrials.gov identifier: NCT00364741.
Background
Surgical site infection is a common and serious complica-
tion after abdominal surgery [1]. It is essential to optimize
perioperative conditions because the first hours following
bacterial contamination are critical for establishing the
wound infection [2]. Wound oxygen tension is often low
at the end of surgery and this is unfortunate, because bac-
terial eradication depends on this factor via oxidative kill-
ing by neutrophils [3-6]. The incidence of surgical site
infections may therefore be reduced by increasing the
perioperative arterial oxygen tension through increased
inspiratory oxygen fraction.
Before we initiated our multicenter trial "PeRioperative
OXygen Fraction – effect on surgical site Infection and
pulmonary complications after abdominal surgery"
(PROXI), we undertook a meta-analysis on trials compar-
ing the effect of perioperative inhaled oxygen fraction of
0.80 with 0.30 on the frequency of surgical site infection.
This was performed using the trial sequential analysis
method [7-9] and in accordance with international rec-
ommendations [10,11].
When searching MEDLINE, Cochrane Central Register of
Controlled Trials, and EMBASE (search terms, see Appen-
dix) four clinical trials including 1003 patients were
found [12-15].
In a random-effects model, the overall pooled effect of an
inspiratory oxygen fraction of 0.80 was a reduction of the
occurrence of surgical site infections. The relative risk
reduction was 19% [95% CI: -68% to 61%], P = 0.57, but
a large heterogeneity, I2 = 74%, was also found (Fig. 1).
This may primarily be explained by the findings in one
Meta-analysis comparing perioperative inspiratory oxygen fractions of 0.80 and 0.30/0.35 on surgical site infection Figure 1
Meta-analysis comparing perioperative inspiratory oxygen fractions of 0.80 and 0.30/0.35 on surgical site infec-
tion.
Review: Perioperativ Oxygen Fraction
Comparison: 01 FiO2=0.80 vs. (FiO2=0.30 / 0.35)                                                                           
Outcome: 01 Surgical Site Infection                                                                                    
Study  FiO2=0.80  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Without  nitrousoxid
 Greif                      13/250             28/250         28.76      0.46 [0.25, 0.88]        
 Belda                      22/148             35/143         31.67      0.61 [0.38, 0.98]        
 Mayzler                     2/19               3/19          12.57      0.67 [0.13, 3.55]        
Subtotal (95% CI) 417                412  72.99      0.56 [0.38, 0.81]
Total events: 37 (FiO2=0.80), 66 (Control)
Test for heterogeneity: Chi² = 0.49, df = 2 (P = 0.78), I² = 0%
Test for overall effect: Z = 3.08 (P = 0.002)
02 With nitrousoxid
 Pryor                      20/80               9/80          27.01      2.22 [1.08, 4.58]        
Subtotal (95% CI) 80                 80  27.01      2.22 [1.08, 4.58]
Total events: 20 (FiO2=0.80), 9 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.03)
Total (95% CI) 497                492 100.00      0.81 [0.39, 1.68]
Total events: 57 (FiO2=0.80), 75 (Control)
Test for heterogeneity: Chi² = 11.62, df = 3 (P = 0.009), I² = 74.2%
Test for overall effect: Z = 0.57 (P = 0.57)
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trial [15], in which the high oxygen fraction was associ-
ated with an increase in the frequency of surgical site
infection of 122% [95% CI: 8% to 458%]. In that trial,
however, mixtures of oxygen and nitrous oxide were
given, the surgical site infections were assessed retrospec-
tively by chart review, and the allocation was not fully
concealed.
When inspired in a high concentration, oxygen may result
in pulmonary complications, but although 1003 patients
have participated in the previous trials [12-15], this
important question has been studied only in 30 patients
[16]. This subgroup of patients from the first trial of sup-
plemental oxygen [13] underwent pulmonary function
test together with chest radiographs and computed tom-
ography (CT) scans on the day after surgery. A high oxy-
gen fraction was not found to be associated with
significant changes in any test, but CT-determined atel-
ectasis tended to be more common in patients receiving
80% oxygen (94% vs. 64%, P = 0.12). Preoxygenation
with 100% oxygen for 5 minutes has also been associated
with increased risk of atelectasis formation when com-
pared to 60% [17]. A high oxygen fraction has also been
related to harms such as an increased risk of airway
inflammation [18], poor regulation of blood glucose [19],
changes in the cardiac index [20], and to benefits such as
improved healing of colorectal anastomosis [21] and
reduced frequency of postoperative nausea and vomiting
[22,23].
We designed the PROXI-Trial to assess the potential bene-
fits and harms of a high perioperative oxygen fraction in
patients undergoing laparotomy, the primary end point
being surgical site infection.
Methods and design
Trial design
The PROXI-Trial is an ongoing, randomized, parallel
group, multicenter, patient- and assessor blinded trial,
launched on October 9, 2006. The trial is investigator ini-
tiated and controlled. The primary aim is to assess the
effect of a high perioperative oxygen fraction on the fre-
quency of surgical site infection in patients undergoing
laparotomy. The secondary outcome measures are: atel-
ectasis, pneumonia, respiratory failure, re-operation, mor-
tality, duration of postoperative hospitalization, and
admission to intensive care unit. Fourteen anaesthesia
and surgical centres as well as one trial unit in Denmark
participate in the trial.
Inclusion criteria
Patients, aged 18 years or older, scheduled for acute or
elective laparotomy are eligible for inclusion. When the
laparotomy is indicated for a gynaecological disease, only
patients with suspected malignancy (defined as risk of
ovarian malignancy index >200 [24] or a specimen show-
ing atypical or neoplastic cells) are included.
Exclusion criteria
The exclusion criteria are: Surgery performed under gen-
eral anaesthesia within 30 days, chemotherapy for malig-
nancy within 3 months, inability to give informed
consent, and preoperative arterial haemoglobin oxygen
saturation below 90% assessed by pulse oximetry without
supplemental oxygen.
Randomization
The patients are randomized 1:1 by a central interactive
voice-response system at the Copenhagen Trial Unit to
ensure adequate allocation concealment. A computer gen-
erated randomization sequence with variable block size is
used with the following stratification variables: Centre,
diabetes mellitus, acute or elective surgery, and body mass
index (<30 or ≥30 kg/m2).
Intervention
After induction of anaesthesia and tracheal intubation,
patients randomized into the supplemental oxygen group
are given an inspiratory oxygen fraction (FiO2) of 0.80
until end of surgery. Patients are administered a FiO2 of
0.80 during the first two hours following extubation by
means of a non-rebreathing face mask with a reservoir
(High Concentration Oxygen Mask, Intersurgical Ltd,
Wokingham, UK) with a flow of 14 litres of oxygen and 2
litres of air per minute. This mixture of oxygen and air
contains a slightly higher oxygen fraction (0.901),
because even the manufacturer's test resulted in only 85%
delivered oxygen in a situation with masks fully sealed to
a flat surface and 15 litres of oxygen per minute (Intersur-
gical Test Report, April 2008). With an estimated flow of
ambient air into the mask of approximately 3.0 litres per
minute, we estimate that the chosen mask and mixture
delivers a FiO2 close to 0.80. This was confirmed in a test
before the trial was initiated.
The patients randomized into the control group are given
a FiO2 of 0.30 after tracheal intubation and until extuba-
tion, after which they receive a flow of 2 litres of oxygen
and 14 litres of air per minute through a non-rebreathing
facemask with reservoir (High Concentration Oxygen
Mask, Intersurgical Ltd, Wokingham, UK).
In both groups, it is allowed to increase FiO2 if hypoxia is
detected or suspected in order to keep the arterial oxygen
saturation above 94% and the arterial oxygen tension
above 9 kPa. Positive end expiratory pressure (PEEP) is
used at a level chosen by the attending anaesthetist. At the
end of the intervention period, oxygen is administrated
only at the physician's discretion and according to usual
clinical practice.Trials 2008, 9:58 http://www.trialsjournal.com/content/9/1/58
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Blinding
Cardboard shields are placed on the side of the anaesthe-
sia machines to keep the surgical team blinded to group
allocation. In the post anaesthesia care unit, opaque bags
cover the flow meters. Information about perioperative
FiO2, arterial oxygen partial pressure (PaO2) as well as flow
of oxygen and air is collected on a separate paper form,
placed in a sealed opaque envelope when patients are dis-
charged from the post anaesthesia care unit. Any urgency
requiring opening of the envelope will be reported. The
patients are not informed of their group allocation during
the trial or follow-up.
Patients are asked after follow-up which group they
believe they were allocated to in order to evaluate patient
blinding and the possible related bias in the reporting of
adverse events. If patients answer supplemental oxygen or
control group, they are asked to indicate why.
The Steering Committee is also blinded and has no access
to patient allocation during the trial. An independent stat-
istician will analyze the PROXI data under code (treat-
ment A and B) and prepare a blinded version of the
results. All sections of the manuscript, including the dis-
cussion and conclusion, will be written in two versions;
one assuming treatment A is supplemental oxygen and
treatment B is control treatment, and another manuscript
based on the reverse assumption [25]. All authors must
approve both versions before demasking the allocation
groups.
Standard treatment
After preoxygenation, anaesthesia is induced with propo-
fol or thiopental supplemented with remifentanil, fenta-
nyl, sufentanil, or alfentanil and maintained with
propofol, sevoflurane, or desflurane. The use of nitrous
oxide is not allowed. Tracheal intubation is facilitated
with succinylcholine or an intermediate acting non-depo-
larizing neuromuscular blocking agent. Both groups are
given a FiO2 of 1.0 until tracheal intubation and again
immediately before extubation. The patients are venti-
lated to assure normocapnia (defined as an arterial carbon
dioxide tension of 4.5 to 6.0 kPa if arterial blood sampling
is carried out, otherwise capnography is used to adjust
ventilation).
Several important elements of the perioperative care [26-
30] are stressed in the trial protocol (Table 1). The proto-
col recommends cefuroxime 1.5 g and metronidazole 1.0
g given intravenously as standard antibiotic choice, but we
define appropriate antibiotic therapy according to Table
2[31] because of the high number of surgical procedures.
Antibiotic therapy must be given within 60 minutes of
skin incision, and we consider 'timely administration' to
be fulfilled if the first and second antibiotic is given before
skin incision.
Baseline data
After inclusion we record demographic characteristics and
data on significant comorbidity with emphasis on the fol-
lowing factors: Current smoking, ethanol consumption
above 48 g daily, diabetes mellitus, concurrent infection,
Table 1: Trial protocol for perioperative care of patients undergoing laparotomy.
Protocol element Description
Preoperative:
Bowel preparation No routine oral preparation used for colonic resection.*
Fasting guideline Allowed to drink clear fluids 2 hours before anaesthesia.*
Perioperative:
Epidural analgesia Placed at thoracic level corresponding to the incision in elective procedures and used intraoperatively.*
Fluid therapy A preoperative deficit in acute surgery corrected preoperatively, but no routine fluid preload used. Fluid given only to 
replace measured or calculated deficits (no third space loss) aiming at a body weight increase less than 1 kg. Peroperative 
blood loss replaced 1:1 with colloids, not exceeding 500 mL more than estimated blood loss. Blood transfusion initiated 
if blood loss exceeds 20 mL/kg, considering the patient's haematocrit. Vasopressors or reduction of epidural infusion if 
hypotension.¤
Temperature control Warmed fluids if large infusions and upper body air-warming device used. Core temperature measured continuously, 
aiming at 36 to 37°C.*
Glucose control Aim: Blood concentration between 5 and 11 mmol/L.
Surgical technique Shortest possible abdominal incision. No intraabdominal drain, no nasogastric tube unless essential for intraoperative 
gastric decompression, postoperative ileus prophylaxis or postoperative nutrition.*
Neuromuscular function Monitored with a nerve stimulator; patients are not extubated before train-of-four ratio is above 0.90.#
Postoperative:
Pain relief Epidural analgesia continued for 2 days postoperatively. Paracetamol 4 g daily and a non-steroidal anti-inflammatory drug 
before discontinuing the epidural analgesia. An opioid is given intravenously if pain score at rest is above 3 on visual 
analogue scale (0–10).*
Fluid therapy Oral intake as early as possible, blood loss replaced 1:1 with colloids or blood transfusion according to normal clinical 
practice. Other deficits replaced with crystalloids in order to keep urine output above 1 mL/kg/hr.¤
* Fearon et al. [26]; # Berg et al. [27]; ¤ Arkilic et al., Kabon et al., Brandstrup et al. [28-30].Trials 2008, 9:58 http://www.trialsjournal.com/content/9/1/58
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or immunosuppressive disease, chronic obstructive pul-
monary disease (COPD) and other pulmonary diseases.
The risk of infection is evaluated with the National Noso-
comial Infections Surveillance System (NNISS) and the
Study on the Efficacy of Nosocomial Infection Control
(SENIC) scores [32,33].
Perioperative data collection
Preoperative haemoglobin and peroperative change in
blood glucose are measured. We record duration of anaes-
thesia, duration of surgery, placement of epidural cathe-
ter, type of anaesthesia, body core temperature at the end
of surgery, and use of antibiotics, vasopressors, and dex-
amethasone. We record peroperative blood loss and the
administered volume of crystalloids, colloids, and blood.
Pre- and postoperative body weight is also measured, if
possible.
Follow-up
All patients must be seen daily in the postoperative period
by a surgical investigator blinded to the allocated inter-
vention. A follow-up visit is scheduled between the 13th
and the 30th postoperative day as appropriate. The pri-
mary and secondary outcome measures are evaluated at
each visit and additional information about wound char-
acteristics in the postoperative period is collected to calcu-
late the ASEPSIS score (Additional treatment, Serous
exudate, Erythema, Purulent exudate, Separation of deep
tissues, Isolation of bacteria and duration of inpatient
Stay) [34]. This score (range 0–70) combines wound
appearance the first 5 postoperative days with additional
surgical treatment and a score higher than 20 indicates
wound infection [34].
Patients presenting with symptoms of pulmonary compli-
cations are examined according to routine clinical practice
by the attending physician, including chest radiographs or
CT, when relevant. All chest radiographs and CT's are eval-
uated for infiltrate and atelectasis by the attending radiol-
ogist, who is unaware of the administered intervention.
Outcome measures
The primary outcome is surgical site infection within 14
days, defined according to the criteria by Center of Disease
Control and prevention (CDC) [35]. This definition
includes superficial, deep, and organ/space infections and
surgical site infection is considered present if any of these
infections are diagnosed during follow-up. If a patient has
a combination of superficial, deep, and organ/space infec-
tions, we report the deepest infection, except from organ/
space infections that drain through the incision, which
according to CDC is a deep surgical site infection [35].
The secondary outcomes are defined as follows (intervals
defined as time after surgery):
￿ Pneumonia within 14 days, defined according to the cri-
teria by CDC [36]. We will report the frequencies within
this category of: Nosocomial pneumonia, ventilator-asso-
ciated pneumonia, pneumonia due to gross aspiration,
and pneumonia in immunocompromised patients [36].
￿ Atelectasis within 14 days is defined to be present if
described in the radiologist's evaluation of chest radio-
graph or CT.
￿ Respiratory failure within 14 days, defined as need for
controlled ventilation or arterial oxygen saturation below
90% despite supplemental oxygen.
￿ Mortality within 30 days.
￿ Duration of postoperative hospitalization, including
readmission periods, if occurring within 30 days.
Table 2: Adequate perioperative intravenous antibiotic prophylaxes.
Type of surgery Adequate perioperative antibiotic prophylaxis
Elective colorectal surgery B or C
Elective gynaecological surgery
Clean procedures A
Clean-contaminated, contaminated or dirty infected procedures B or C
Elective removal of gall bladder None
Acute appendectomy, no perforation None
Acute appendectomy, with perforation B or C
Other acute laparotomy,
Clean procedures None
Clean-contaminated, contaminated or dirty infected procedures B or C
A = cefuroxime 1.5 g; B = cefuroxime 1.5 g and metronidazole 1.0 g; C = ampicillin 2 g or benzylpenicillin 2 million IU in combination with 
gentamicin 0.240 g and metronidazole 1.0 g.
Adequate antibiotic prophylaxes divided by surgical procedure are based on the advisory statement from the National Surgical Infection Prevention 
Project [31].Trials 2008, 9:58 http://www.trialsjournal.com/content/9/1/58
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￿ Admission to the intensive care unit within 14 days, if
not part of the postoperative care.
￿ Abdominal re-operation due to any reason within 14
days.
In case of uncertain outcome measures, two blinded asses-
sors, and a third assessor in case of further disagreement,
review the patient's hospital record.
Adverse events
All recorded adverse events will be reported according to
the CONSORT Statement [37]. We do not list any adverse
events specifically related to supplemental oxygen in the
protocol or consent form. The following adverse events
are considered so frequent after surgery that they are not
recorded: Pain or hypotension within the first 3 postoper-
ative days and abnormal laboratory values that do not
require medical treatment. All other adverse events are
collected prospectively in the patient's case report form
and specifically addressed at the follow-up visit. The
reported adverse events will be categorized before the
trial's allocation groups are demasked.
An adverse event is considered serious if it is fatal, life
threatening, causing permanent disability or requiring
prolonged hospitalization. Adverse events and serious
adverse events will be reported for all randomized
patients separately as frequencies for each arm. It will be
reported if any adverse event results in increase or
decrease of the allocated FiO2.
Missing data
If patients do not meet for the follow-up visit, we contact:
Hospital outpatient clinics, emergency departments, and
the patient's family physician. Wound evaluation carried
out in accordance with the CDC-criteria is considered ade-
quate. In the remaining cases, the patients are interviewed
by telephone, and the information obtained is used in the
intention-to-treat analysis.
Missing data from daily evaluation of wound characteris-
tics for the ASEPSIS score will be replaced by scores
obtained by linear regression of score by day using the
scores from the adjacent days. Missing data in patients dis-
charged before 5th postoperative day will be replaced by
scores obtained by linear regression of score by day
between the adjacent in-hospital score and the score at the
follow-up visit [38].
Patients meeting the inclusion criteria without being ran-
domized are prospectively recorded. Completeness of
these data is established through the Danish Anaesthesia
Database http://www.kliniskedatabaser.dk and the Dan-
ish National Patient Registry [39] by searching the rele-
vant Health Service Classification System (SKS)-codes for
laparotomy procedures http://www.medinfo.dk/sks/
brows.php.
Major protocol violations
Patients with the following major protocol deviations will
not be included in the per protocol analysis: Not meeting
the inclusion criteria, fulfilling an exclusion criterion, FiO2
above 0.60 for more than 1 hour in the control group,
FiO2 below 0.60 for more than 1 hour in supplemental
oxygen group, failure to use the oxygen mask more than 1
hour, no in-hospital evaluation of the outcomes for 4 con-
secutive days or more, no follow-up visit between 13th and
30th postoperative day, and unblinded outcome assess-
ment. We considered the limit of FiO2 = 0.60 to represent
the lowest oxygen fraction where atelectasis could not be
attributed to the oxygen concentration [17].
Trial conduct and monitoring
Data are collected on printed case report forms, on which
a unique barcode number is printed in order to eliminate
possibilities of duplication of the case report forms. Case
report forms are scanned to the database using the Verity
Teleform® system (Verity, Sunnyvale, California, USA),
which may have an even higher accuracy than manual
transfer of data to an electronic database by double data
entry.
Statistics
All data will be analyzed according to a predefined plan.
Only the primary and secondary outcomes and serious
adverse events will be compared statistically. Outcome
measures will be analyzed for all randomized patients in
the intention-to-treat analysis, which will be the primary
results of the trial. According to the International Confer-
ence on Harmonization Good Clinical Practice (ICH-
GCP) guidelines for analyses of randomized clinical trials
of medicinal products No 9 [40] univariate analyses will
be carried out for all outcome measures. In multivariate
analyses, the intervention effects will be adjusted by the
following covariates being the stratification variables: cen-
tre, diabetes mellitus, acute or elective surgery, and body
mass index (<30 or ≥30 kg/m2) as well as the following:
COPD, daily smoking, surgical incision extending above
the umbilical transversal, duration of surgery, and age
(<40 or ≥40 years). All intervention effect estimates will
be given with 95% confidence limits and a two-tailed P-
value < 0.05 considered significant.
Sample size
We estimated the frequency of surgical site infection to be
16% in the control group. This was based on the previ-
ously reported frequencies [12-15] and the inclusion of
acute laparotomies in our trial. A fixed effects meta-analy-
sis  model showed a relative risk reduction of 25% if all 4Trials 2008, 9:58 http://www.trialsjournal.com/content/9/1/58
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trials are included  and 45% if the Pryor trial [15] were
excluded. We thus expected a relative risk reduction of
33%. We calculated that a total sample size of 1400
patients would allow us to detect or reject a difference in
surgical site infection between 16% and 10.7%, with 5%
type 1 error risk, 80% power, and 10% dropout.
Trial sequential analysis of cumulative meta-analysis
In a single trial, interim analyses increase the risk of type I
error. To avoid an increase of overall type I error, monitor-
ing boundaries can be applied to decide whether a single
randomized trial could be terminated early because of the
P-value being sufficiently small. Because no reason exists
why the standards for a meta-analysis should be less rigor-
ous than those for a single trial, analogous trial sequential
monitoring boundaries can be applied to meta-analysis as
trial sequential analysis [7-9]. The underlying assumption
for this analysis is that significance testing is performed
each time a new trial is published. Trial sequential analy-
sis depends on the quantification of the required informa-
tion size. Cumulative meta-analysis of trials are at risk of
producing random errors, because repetitive testing of
accumulating data runs the risk of random errors and the
information size requirement, analogous to the sample
size of a single optimally powered clinical trial, is not met.
Information size calculations were based on an assump-
tion of a plausible relative risk reduction with an a priori
relative risk reduction of 33% surgical site infections. The
trial sequential analysis [7] adjusting for repeated testing
on accumulating data shows that we still lack sufficient
information dependent of the Pryor trial [15]. If all trials
were included, neither the trial sequential monitoring
boundary nor the traditional boundary (P < 0.05) were
crossed (Fig. 2), and the required heterogeneity adjusted
information size is 5051 to reliably detect or reject a rela-
tive risk reduction of 33% with a type I error risk of 5%
and a type II error risk of 20%. If the Pryor trial [15] is
excluded, the cumulative meta-analysis may be conclusive
adjusted for repeated significance testing in cumulative
meta-analysis, as the trial sequential monitoring bound-
ary is crossed during the second trial (Fig. 3). As this post
hoc exclusion of one of the trials testing FiO2 = 0.80 vs.
FiO2 = 0.35 may be biased, we therefore concluded, con-
sidering the result of the meta-analysis of all the trials, that
there may still be an information gap of more than a thou-
sand randomized patients. So we calculated that 1400
patients must be randomized and assessed to reliably con-
firm a detection or rejection of a 33% relative risk reduc-
tion of surgical site infections after abdominal surgery
with FiO2 = 0.80 vs. FiO2 = 0.30.
Data Monitoring Committee
An independent Data Monitoring Committee (DMC) was
established to evaluate safety and efficacy at one sched-
uled interim analysis. This took place when the first of the
following three events occurred: Follow-up of the first 700
patients, ninety patients diagnosed with surgical site infec-
tion or 100 diagnosed with pneumonia. Primary and sec-
ondary outcome measures, occurrence of any serious
adverse event and occurrence of any non-serious adverse
event were presented to the DMC under blinded codes for
the 2 arms of the trial. The DMC could advise the steering
committee to stop the trial if the interim analysis demon-
strated:
￿ Conclusive evidence of a decreased frequency of the pri-
mary outcome measure (benefit) with a high oxygen frac-
tion, with a P-value < 0.001 against the control group.
￿ Conclusive evidence for increased frequency of the pri-
mary outcome measure (harm) with a high oxygen frac-
tion, with a P-value < 0.01 against the control group.
￿ Number and nature of serious adverse events out-
weighed by any potential benefits.
The DMC recommended continuing the trial after the
interim analysis held on January 24, 2008, with 563
patients analyzed as more than ninety patients had a sur-
gical site infection at that time.
Ethical considerations
The PROXI-Trial is conducted in compliance with the Hel-
sinki Declaration and approved by the Research Ethics
Committee of Copenhagen and Frederiksberg (protocol
No H-KF-306766), the Danish Medicines Agency (proto-
col No 2612-3165), and the Danish Data Protection
Agency (protocol No 2006-41-6738). The trial is regis-
tered at http://www.clinicaltrials.gov (NCT00364741).
All patients sign written informed consent before arrival
to the operating room. The trial is conducted and moni-
tored according to the ICH-GCP guidelines [41]. Case
report forms are checked for validity and internal consist-
ency through centre visits where source data are inspected.
Trial status
In the beginning of September 2008, a total of 1350
patients are enrolled at the 14 participating centres: Rig-
shospitalet (n = 273), Bispebjerg Hospital (n = 152), Vejle
Hospital (n = 138), Herlev Hospital (n = 128), Amager
Hospital (n = 113), Nykobing Falster Hospital (n = 106),
Slagelse Hospital (n = 99), Aarhus Hospital (n = 90),
Svendborg Hospital (n = 79), Naestved Hospital (n = 62),
Viborg Hospital (n = 57), Gentofte Hospital (n = 39), Hol-
baek Hospital (n = 8), Kolding Hospital (n = 6).
Discussion
The benefits of a high perioperative oxygen fraction on
surgical site infections may be substantial, but a consider-
able gap of information exists before this is firmly estab-Trials 2008, 9:58 http://www.trialsjournal.com/content/9/1/58
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lished. Furthermore, potential harms from a high oxygen
fraction, primarily pulmonary complications, have not
been adequately assessed.
Some additional trials suggest that a high oxygen fraction
in the perioperative period is beneficial. Firstly, patients
undergoing nitrous oxide-free anaesthesia with 80% oxy-
gen had fewer wound infections than patients receiving
nitrous oxide-based (70% N2O, 30% oxygen) anaesthesia
[42]. The higher oxygen concentration could have con-
tributed significantly to this difference, because nitrous
oxide may not be a risk factor for wound infections [43].
Secondly, another large trial investigating treatment of
hypoxia via continuous positive airway pressure in the
postoperative period also demonstrated a reduction in
wound infections [44]. However, even if the nitrous-oxide
trial [42] is incorporated in the trial sequential analysis,
there is still a gap of information of approximately 1500
patients to reject an intervention effect of 33% relative risk
reduction (Fig. 4).
Strengths
Our trial is the first trial to report potential benefits as well
as harms in all patients receiving supplemental oxygen.
This is strengthened as a consequence of the mandatory
monitoring according to the ICH-GCP standards [41],
including adverse events.
The low-bias design [45] and large sample size allows us
to reliably detect even smaller intervention effects than
Trial sequential analysis with a required information size of 5051 Figure 2
Trial sequential analysis with a required information size of 5051. A priori heterogeneity adjusted information size 
(APHIS) based on an a priori relative risk reduction (RRR) of 33% with a type I error risk of 5% and a power of 80%. The 
cumulative z-curve constructed for a random effects model as heterogeneity is 74% crosses the traditional boundary (P = 0.05) 
once and return to non-significant values. The cumulative z-curve never crosses the trial sequential monitoring boundary. 
Despite 989 patients randomized we may still need more than 4000 randomized participants to close the information gap con-
sidering repeated analyses of accumulating data.
 
 
 
Cummulative 
Z-Score  RRR 33% APHIS = 5051 
Z-curve 
989  Number of patients  
linear scaled 
RRR 33% APHIS = 5051 Trials 2008, 9:58 http://www.trialsjournal.com/content/9/1/58
Page 9 of 13
(page number not for citation purposes)
the four previous trials [12-15]. We furthermore report
surgical site infections according to the CDC-criteria [35],
which also consider the most severe surgical site infection;
the organ/space infection.
In addition, the PROXI-Trial is the first investigation of
supplemental oxygen including acute patients. Apart from
higher rates of peroperative contamination, these patients
may have more cardiovascular and pulmonary comorbid-
ity than elective patients and accordingly a higher risk for
low local tissue oxygen partial tension, which could
increase the benefit of a high oxygen fraction. On the
other hand, these patients are also more prone to postop-
erative pulmonary complications and a potential harm of
a high oxygen fraction cannot be excluded either.
We choose to include gynaecological cancer surgery,
because this account for a large and increasing proportion
of laparotomies, as increasing numbers of colorectal pro-
cedures are now performed laparoscopically. We believe
this may strengthen the external validity of the trial and
the generalizability of the trial results. Patients with
benign gynaecological conditions are not considered for
inclusion. This was decided because we primarily sought
to include patients with a high risk of surgical site infec-
tions, thus avoiding low power to detect or reject an inter-
Trial sequential analysis excluding the trial of Pryor Figure 3
Trial sequential analysis excluding the trial of Pryor. Meta-analysis of the trials by Greif [13], Belda [12] and Mayzler 
[14], excluding the trial of Pryor [15] with a required information size of 1304 (APIS, a priori information size) based on an a 
priori relative risk reduction (RRR) of 33% and a type I error risk of 5% and a power of 80%. The cumulative z-curve con-
structed for a fixed-effect model as heterogeneity is 0% crosses both the traditional boundary (P = 0.05) after the first trial and 
the trial sequential monitoring boundary during the second trial. So there may be evidence for an effect of at least 33% RRR in 
a cumulative meta-analysis of trials investigating a high oxygen fraction when the Pryor trial is excluded when adjusting for 
repeated analyses of accumulating data.
 
 
 
Cummulative 
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Z-curve 
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vention effect. The frequency of surgical site infection is
estimated to be only 2% in patients with American Society
of Anesthesiologists physical status score I-II undergoing
clean or clean-contaminated abdominal hysterectomy
with a duration of surgery less than 2 hours [1] and 4%
after abdominal hysterectomy for benign conditions [46].
The stratified randomization is used to avoid skewed allo-
cation of patients with important prognostic factors for
surgical site infection and allows us to adjust intervention
effect estimates for the stratification variables (diabetes
mellitus, obesity and acute surgery) with the highest
power. The lack of such stratification was a major limita-
tion in the trial by Pryor et al. [15]. With stratification for
center, we furthermore match the different distribution of
surgical procedures in the participating hospitals.
Limitations
Some important limitations must be noted. Firstly, some
patients in the control group may need more than the
allocated 30% oxygen in order to keep arterial oxygen sat-
uration above 94%. However, this practice is in accord-
ance with clinical practice and we believe such pragmatic
nature of the intervention is important. Our per protocol
analysis will assess if close adherence to the protocol is
associated with better outcome.
Trial sequential analysis of all trials irrespective of adjuvant inhaled gases Figure 4
Trial sequential analysis of all trials irrespective of adjuvant inhaled gases. The effect of 80% oxygen vs. 30% oxygen 
on surgical site infections calculated in cumulative meta-analysis of all trials irrespective adjuvant inhaled gases (the trials by 
Greif [13], Pryor [15], Belda [12], Mayzler [14] and Myles [42]). The low-bias heterogeneity adjusted information size (LBHIS) 
is 4500 based on a relative risk reduction (RRR) suggested by the low-bias trials of 33% and a meta-analytic estimate of the fre-
quency of surgical site infection in the control group (30% oxygen) on 14% with a type I error risk of 5% and a power of 80%. 
No crossing of the trial sequential monitoring boundary at any time despite P < 0.05 after the first trial [13]. The gap of infor-
mation to reject an intervention effect of 33% relative risk reduction is approximately 1500 patients.
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Secondly, we are not able to apply all elements of the
standard treatment to all patients. Timely administration
of antibiotics and epidural analgesia influences postoper-
ative outcome, but this is not possible to achieve in all
patients. The antibiotic regimen is recorded to assess
whether it is adequate for the given type of surgery and the
most common pathogenic bacterial flora. Protocol devia-
tions may result in a higher frequency of surgical site
infection, but that may reflect clinical practice.
Thirdly, it is possible that the mixture of different surgical
procedures may be associated with the risk of overlooking
a beneficial effect related to specific surgical procedures,
such as colorectal resections, but the type of surgery is not
always known at the time of deciding the inspiratory oxy-
gen fraction and we are aiming at elucidating the effect of
a high oxygen fraction in connection with open gastroen-
terological procedures in general, including emergency
surgery.
Conclusion
We believe our pragmatic trial design increases the exter-
nal validity, because the protocol is in accordance with
clinical practice. We anticipate that the results of this trial
may be generalizable to a general surgical population
undergoing laparotomy.
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Appendix
A non-language restricted search string for PUB MED
search of randomized trials for the effect of perioperative
supplemental oxygen for surgical site infection.
"Surgical" [Text Word] AND "infection" [Text Word] AND
"oxygen" [Text Word] AND "Randomized Controlled
Trial" [ptyp] AND "adult" [MeSH Terms] AND "homini-
dae" [MeSH Terms].
Initial search February 2006, last update September 2008.
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